Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Grade 3 ...

Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Forward-Looking Statements This ...

To all practitioners who have broken into a cold sweat after trusting 'AI research results''Where exactly in the primary ...

A new graph neural network framework evaluates dance training in real time and automatically adapts practice plans, achieving ...

After hyping previous claims, tech giant doesn’t comment on inquiries about lack of novelty in database of AI-generated ...

Extracting from structure rather than generating informationThe amount of information on the internet continues to ...

Researchers have developed IGA, an unsupervised graph alignment framework that uses isomorphism-aware neural networks to ...

The revised Tempus contract extends to six years, removing Recursion Pharmaceuticals’ right to terminate for convenience. Annual payments for the third through fifth anniversaries are set at ...

Recursion Pharmaceuticals will pay Tempus $42 million over the next three years under a data license agreement. The companies extended their data partnership, first signed in 2023, through November ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies ...